home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
HaCKeRz KrOnIcKLeZ 3
/
HaCKeRz_KrOnIcKLeZ.iso
/
drugs
/
60.fr.35050
< prev
next >
Wrap
Text File
|
1996-05-06
|
12KB
|
216 lines
<ARTICLE>
Date="07/05/95"
Citation="60 FR 35050"
Group="legal"
Type="NOTICE"
Department="DEPARTMENT OF JUSTICE"
Agency="DRUG ENFORCEMENT ADMINISTRATION (DEA), JUSTICE"
Subject="1995 Revised Aggregate Production Quotas for Controlled Substances in Schedules I and II"
<HEADER>
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 132F]
1995 Revised Aggregate Production Quotas for Controlled Substances
in Schedules I and II
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final revised aggregate production quotas
for 1995.
</HEADER>
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 132F]
1995 Revised Aggregate Production Quotas for Controlled Substances
in Schedules I and II
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final revised aggregate production quotas
for 1995.
+
------------------------------------------------------------
SUMMARY: This notice establishes revised 1995 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act (CSA).
DATES: This order is effective on July 5, 1995.
FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, D.C. 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C.
826) requires the Attorney General to establish aggregate production
quotas for controlled substances in Schedules I and II each
year. This responsibility has been delegated to the Administrator
of the DEA pursuant to Section 0.100 of Title 28 of the Code
of Federal Regulations. The Administrator, in turn, has redelegated
this function to the Deputy Administrator of the DEA pursuant
to Section 0.104 of Title 28 of the Code of Federal Regulations.
On May 9, 1995, a notice of the proposed revised 1995 aggregate
production quotas for controlled substances in Schedules I and
II was published in the Federal Register (60 FR 24649). All
interested parties were invited to comment on or object to these
proposed aggregate production quotas on or before June 9, 1995.
Several companies commented that the revised 1995 aggregate
production quotas for amphetamine, diphenoxylate, fentanyl,
hydrocodone, hydromorphone, methadone, methadone intermediate
(for conversion), methylphenidate, morphine and oxycodone (for
sale), were insufficient to provide for the estimated medical,
scientific, research and industrial needs of the United States,
for export requirements and for the establishment and maintenance
of reserve stocks.
The DEA has reviewed the involved companies' 1994 year-end
inventories, their initial 1995 manufacturing quotas, 1995 export
requirements and their actual and projected 1995 sales. Based
on this data, the DEA has adjusted the revised 1995 aggregate
production quotas for amphetamine, diphenoxylate, fentanyl,
hydromorphone, methadone, methadone intermediate (for conversion),
morphine and oxycodone (for sale) to meet the estimated medical,
scientific, research and industrial needs of the United States.
Regarding hydrocodone and methylphenidate, the DEA has decided
that no adjustments are necessary to meet the 1995 estimated
medical, scientific, research and industrial needs of the United
States.
The Office of Management and Budget has determined that notices
of aggregate production quotas are not subject to centralized
review under Executive Order 12866. This action has been analyzed
in accordance with the principles and criteria contained in
Executive Order 12612, and it has been determined that this
matter does not have sufficient Federalism implications to warrant
the preparation of a Federalism Assessment.
The Deputy Administrator hereby certifies that this action
will have no significant impact upon small entities whose interests
must be considered under the Regulatory Flexibility Act, 5 U.S.C.
601, et seq. The establishment of aggregate production quotas
for Schedules I and II controlled substances is mandated by
law and by international treaty obligations. While aggregate
production quotas are of primary importance to large manufacturers,
their
---- page 35051 ----
impact upon small entities is neither negative nor beneficial.
Accordingly, the Deputy Administrator has determined that this
action does not required a regulatory flexibility analysis.
Therefore, under the authority vested in the Attorney General
by Section 306 of the Controlled Substances Act of 1970 (21
U.S.C. 826), delegated to the Administrator by Section 0.100
of Title 28 of the Code of Federal Regulations, and redelegated
to the Deputy Administrator of the DEA by Section 0.104 of Title
28 of the Code of Federal Regulations, the Deputy Administrator
hereby orders that the 1995 revised aggregate production quotas,
expressed in grams of anhydrous acid or base, be established
as follows:
-------------------------------------------------------------+-------------------
| Established
Basic class | revised 1995
| quotas
-------------------------------------------------------------+-------------------
|
Schedule I: |
Acetylmethadol ........................................... | 7
Alphacetylmethadol ....................................... | 5
Aminorex ................................................. | 7
Bufotenine ............................................... | 10
Cathinone ................................................ | 9
Difenoxin ................................................ | 14,000
Dihydromorphine .......................................... | 5
2,5-Dimethoxyamphetamine ................................. | 15,650,000
Dimethoxyamphetamine ..................................... | 7
Ethylamine analog of Phencyclidine ....................... | 5
N-Ethylamphetamine ....................................... | 9
Lysergic acid diethylamide ............................... | 56
Mescaline ................................................ | 7
Methaqualone ............................................. | 7
Methcathinone ............................................ | 14
4-Methoxyamphetamine ..................................... | 17
4-Methylaminorex ......................................... | 2
3,4-Methylenedioxyamphetamine ............................ | 17
3,4-Methylenedioxy-N-ethylamphetamine .................... | 27
3,4-Methylenedioxymethamphetamine ........................ | 17
3-Methylfentanyl ......................................... | 14
Normethadone ............................................. | 5
Normorphine .............................................. | 7
Tetrahydrocannabinols .................................... | 35,000
Thiophene Analog of Phencyclidine ........................ | 10
Schedule II: |
Alfentanil ............................................... | 7,000
Amobarbital .............................................. | 15
Amphetamine .............................................. | 1,226,000
Cocaine .................................................. | 550,000
Codeine (for sale) ...................................... | 67,312,000
Codeine (for conversion) ................................. | 16,181,000
Desoxyephedrine .......................................... | 1,154,000
-------------------------------------------------------------+-------------------
(1,138,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product and 16,000 grams for methamphetamine)
-------------------------------------------------------------+-------------------
Dextropropoxyphene ....................................... | 124,012,000
Dihydrocodeine ........................................... | 100,000
Diphenoxylate ............................................ | 965,000
Ecogonine (for conversion) ............................... | 650,000
Ethylmorphine ............................................ | 10
Fentanyl ................................................. | 114,200
Hydrocodone .............................................. | 8,474,000
Hydromorphone ............................................ | 435,500
Isomethadone ............................................. | 10
Levo-alpha-acetylmethadol ................................ | 200,000
Levorphanol .............................................. | 8,000
Meperidine ............................................... | 9,521,000
Methadone ................................................ | 4,388,000
Methadone (for conv) ..................................... | 364,000
Methadone Intermediate (for sale) ........................ | 0
Methadone Int. (for conv) ................................ | 5,533,000
Methylphenidate .......................................... | 10,410,000
Morphine (for sale) ...................................... | 11,145,000
Morphine (for conv) ...................................... | 78,105,000
Noroxymorphone (for sale) ................................ | 21,000
Noroxymorphone (for conv) ................................ | 3,500,000
Opium .................................................... | 1,304,000
Oxycodone (for sale) ..................................... | 4,794,000
Oxycodone (for conv) ..................................... | 25,500
Oxymorphone .............................................. | 10,200
Pentobarbital ............................................ | 15,706,000
---- page 35052 ----
Phencyclidine ............................................ | 72
Phenylacetone (for conv) ................................. | 3,528,000
1-Phenylcyclohexylamine .................................. | 10
1-Piperidinocyclohexanecarbonitrile ...................... | 10
Secobarbital ............................................. | 322,000
Sufentanil ............................................... | 1,600
Thebaine ................................................. | 9,383,000
-------------------------------------------------------------+-------------------
Dated: June 26, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-16321 Filed 7-3-95; 8:45 am]
BILLING CODE 4410-09-M
------------------------------------------------------
The Contents entry for this article reads as follows:
Schedules of controlled substances; production quotas:
Schedules I and II-
1995 aggregate, 35050
</ARTICLE>
.